Geneva, Sept. 23 -- International Clinical Trials Registry received information related to the study (ACTRN12625001007426) titled 'comparison of apremilast and methotrexate in moderate to severe psoriasis patients : a randomized control trial' on Sept. 11.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Primary Sponsor: dr imdad ullah khan - khyber teaching hospital peshawar, dermatology department
Condition:
chronic plaque psoriasis
chronic plaque psoriasis
Skin - Dermatological conditions
Intervention:
apremilast ( a phosphodiesterase 4 inhibitor ) orally 30 mg twice daily for 8 weeks. adherence will be checked by observing the no of tablets take...